Exelixis, Inc. 10-Q Summary: Quarter Ended September 26, 2008
Business Context and Reporting Period
Exelixis, Inc. is a biopharmaceutical company focused on discovering and developing novel small-molecule therapies for cancer and other serious diseases. This report covers the quarterly period ended September 26, 2008 (referred to as September 30, 2008 in financial tables). The company operates primarily through internal research and development and strategic collaborations with major pharmaceutical partners, including Bristol-Myers Squibb, Genentech, and GlaxoSmithKline.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 | Balance Sheet (Sep 30, 2008) |
|---|---|---|---|
| Total Revenues | $29.9 million | $88.3 million | - |
| Net Loss | $(38.5) million | $(124.9) million | - |
| Loss Per Share (Basic/Diluted) | $(0.36) | $(1.19) | - |
| Research & Development Expenses | $65.7 million | $200.5 million | - |
| Cash and Cash Equivalents | - | - | $64.2 million |
| Total Cash, Equivalents & Marketable Securities | - | - | $135.2 million |
| Total Debt (Notes, Bank Obligations, Convertible Loans) | - | - | $123.4 million |
| Accumulated Deficit | - | - | $(916.6) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 12% ($3.1 million) for the quarter and 5% ($4.1 million) for the nine-month period compared to 2007. This was driven primarily by milestone revenues and the acceleration of deferred revenue recognition due to the conclusion of the GlaxoSmithKline collaboration term.
- Increased Net Loss: Net loss widened significantly to $38.5 million for the quarter (from $13.7 million in 2007) and $124.9 million for the nine months (from $66.5 million in 2007). This was largely due to increased R&D spending and the absence of the $18.8 million gain on the sale of the plant trait business recorded in 2007.
- R&D Expenses: R&D expenses rose 12% for the quarter and 21% for the nine months, driven by Phase 3 trial activities for XL184 and Phase 2 activities for XL647.
- Cash Position: Cash and cash equivalents decreased from $135.5 million at year-end 2007 to $64.2 million at September 30, 2008, reflecting a net cash outflow of $71.2 million for the nine-month period.
Guidance, Outlook, and Risks
Strategy Update: Due to capital market turmoil, management plans to reduce net cash usage to align with available cash, aiming to operate independently of capital markets for a substantial period. The company intends to seek new collaborations for clinical assets and significantly reduce total costs while focusing internal efforts on a limited number of programs.
Liquidity and Debt:
- The company anticipates current cash, marketable securities, and available funds under a $150 million Deerfield credit facility will support operations for at least 12 months.
- A significant liability is the $85 million loan from GlaxoSmithKline (totaling $101.1 million with interest as of Sep 30, 2008), with principal and interest due in installments starting October 2009. Repayment may be made in cash or stock.
- The company must maintain specific financial covenants with GlaxoSmithKline (working capital >$25 million; cash and investments >$50 million) and the Deerfield facility (cash and securities >$75 million).
Collaboration Updates:
- GlaxoSmithKline: The six-year collaboration concluded on October 27, 2008. GSK did not select XL184 for further development. Exelixis retains rights to develop unselected compounds subject to a 3% royalty.
- Bristol-Myers Squibb: Exelixis submitted data for XL413; BMS has 30 days to decide on selection, which could trigger a $20 million milestone.
- Genentech: Genentech exercised its option to develop XL518, triggering a $3 million milestone.
Risks: The company faces risks related to the need for additional financing, the uncertainty of clinical trial results, reliance on third-party collaborators, and the potential inability to repay the GlaxoSmithKline loan without dilutive equity issuance or cash outflows.
Investor Verification Checklist
- Liquidity Runway: Verify if the company can maintain the $75 million cash/securities threshold required by the Deerfield facility given the current burn rate.
- GlaxoSmithKline Loan Repayment: Assess the feasibility of repaying the $101.1 million GSK debt due in 2009, particularly the conditions for repayment via common stock in a volatile market.
- Cost Reduction Plan: Monitor the implementation of the announced strategy to reduce costs and the timeline for achieving cash flow alignment.
- XL413 Milestone: Track the outcome of the Bristol-Myers Squibb review of XL413, as a selection would provide a $20 million cash injection.
- SEI Purchase Option: Review the status of discussions regarding the repurchase of assets (XL647, XL784) from Symphony Evolution, Inc., noting the increasing cost of the purchase option over time.